Athenex's intravenous paclitaxel
GPTKB entity
Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
microtubule inhibitor
|
| gptkbp:clinical_trial |
ongoing
combination therapy Phase 3 ongoing studies completed studies monotherapy |
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to paclitaxel |
| gptkbp:dosage_form |
once every 3 weeks
|
| gptkbp:effective_date |
FDA approved
|
| gptkbp:excretion |
biliary excretion
|
| gptkbp:formulation |
solution for infusion
|
| https://www.w3.org/2000/01/rdf-schema#label |
Athenex's intravenous paclitaxel
|
| gptkbp:indication |
gptkb:healthcare_organization
ovarian cancer |
| gptkbp:ingredients |
gptkb:paclitaxel
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P2 C8 inhibitors |
| gptkbp:is_atype_of |
L01 C D01
|
| gptkbp:is_used_for |
treating cancer
|
| gptkbp:lifespan |
approximately 13 hours
|
| gptkbp:manager |
intravenous
IV infusion |
| gptkbp:manufacturer |
gptkb:Athenex,_Inc.
|
| gptkbp:market |
available in the US
available in Europe |
| gptkbp:marketed_as |
Onyvide
|
| gptkbp:packaging |
vial
|
| gptkbp:pharmacokinetics |
highly protein-bound
|
| gptkbp:population |
pediatric patients
adult patients |
| gptkbp:provides_information_on |
ASCO guidelines
NCCN guidelines |
| gptkbp:receives_funding_from |
funded by government grants
funded by private investors |
| gptkbp:research_focus |
biomarker studies
combination with immunotherapy |
| gptkbp:safety_features |
adverse event reporting
post-marketing surveillance |
| gptkbp:scholarships |
gptkb:Educational_Institution
patient assistance programs |
| gptkbp:side_effect |
fatigue
nausea vomiting hair loss neutropenia |
| gptkbp:social_structure |
C47 H51 N O14
|
| gptkbp:storage |
store at room temperature
|
| gptkbp:supply_chain |
direct to hospitals
distributed by wholesalers |
| gptkbp:type_of |
33069-62-4
|
| gptkbp:bfsParent |
gptkb:Athenex
|
| gptkbp:bfsLayer |
3
|